Australian healthcare companies are vigorously engaged in trying to address some of the biggest neglected medical needs in the world. Below are three such companies under investors’ radar, with a robust product pipeline which are currently engaged in further development of their drug candidates.
Imugene Limited (ASX: IMU) is the market pioneer and leader in the development of cancer immunotherapies targeting B-cell peptide vaccines. The product pipeline of Imugene includes most advanced immunotherapy B-cell vaccine candidates in the industry namely PD1-Vaxx, HER-Vaxx, B-Vaxx and a combination of PD-1 and HER-2 vaccines. HER-Vaxx and B-Vaxx are used for the treatment of tumours that over-express the HER-2 receptor such as breast, ovarian, pancreatic, lung and gastric cancers.
Two therapies – HER-Vaxx and B-Vaxx – are currently in Phase 2 clinical phase with a pipeline of other therapies and combinations undergoing earlier stage development. Both these therapies have shown promising Phase 1 clinical trial results. The PD1-Vaxx (that aims to induce the body to produce polyclonal antibodies) as well as combination of HER-2 and PD-1 has shown great potential in preclinical studies with strong inhibition of cancer growth.
Drug Development (Source: Company’s Presentation)
Targeting the rapidly growing Immuno-oncology market, the company’s B cell peptide vaccines provide several potential benefits like inhibiting tumour recurrence with potentially less toxic side effects. The potential benefits of B cell peptide vaccines include low production cost, targeted and lasting immune response, safety and convenience, etc.
As on 3rd June 2019, the company’s stock closed at AUD 0.017 with a market capitalisation of AUD 61.37 million. The stock has generated an impressive long-term return of 55.95 per cent in the last five years.
SUDA Pharmaceuticals Ltd
An Australian pharmaceutical company, SUDA Pharmaceuticals Ltd (ASX: SUD) focusses on the delivery of drugs across the oral mucosa using its OroMist® technology. The company is headquartered in Perth, Western Australia and has an office in Philadelphia, US.
The mucous membrane lining of the oral cavity, which comprises of the cheeks, palate, tongue and gums is known as the oral mucosa. The delivery of drugs via the oral mucosa provides many potential benefits including lower dosage, reduced side effects, ease of use and faster response time.
ZolpiMist™ is a first-in-class oral spray of zolpidem for insomnia, which is marketed in the United States. SUDA also has an exclusive license to market ZolpiMist™ outside the US and Canada. SUDA is also engaged in the development of oro-mucosal sprays of pharmaceutical products for the treatment of malaria, chemotherapy-induced nausea and vomiting, migraine headache, erectile dysfunction, pre-procedural anxiety, PAH, epileptic seizures and cancer. Below figure depicts the Research pipeline at different stages:
Research pipeline (Source: Company’s Website)
SUD settled the day’s trading at AUD 0.004 (As on 3rd June 2019). The stock has delivered an impressive return of 50 per cent in the last one month.
HAVE A LOOK AT SUDA’S PRODUCT PORTFOLIO HERE
Prescient Therapeutics Limited
Clinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) develops novel drugs that depict great promise as potential new therapies for the treatment of several cancers. The company is focussing on the clinical and commercial development of its two drug candidates – PTX-100 and PTX-200.
Its first novel drug candidate – PTX -100 works as an inhibitor of the Ras pathway. PTX -100 has the ability to prevent an important cancer growth enzyme named GGT (geranylgeranyl transferase). PTX-200 (PTX’s second novel drug candidate) inhibits Akt pathway, which plays a vital role in the development of several cancers, including leukemia, ovarian cancer and breast cancer.
PTX-200 is currently undergoing three clinical trials – for ovarian cancer, breast cancer and Relapsed/Refractory Acute Myeloid Leukemia. PTX-100 underwent Phase I trial in advanced solid tumours in which it was well tolerated and achieved stable disease.
The company’s stock ended the day’s trade at AUD 0.043 (As on 3rd June 2019), with a market cap of AUD 16.95 million.
MORE ON PRESCIENT THERAPEUTICS LIMITED CAN BE READ HERE
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.